ASCO 2023 | How to best sequence bispecific antibodies and CAR-T therapy in multiple myeloma
Surbhi Sidana, MD, Stanford University, Stanford, CA, shares her perspectives on how to best sequence of bispecific antibodies and CAR-T therapy in patients with multiple myeloma. Based on emerging data, it seems that it is better to treat patients with CAR-T therapy first. Additionally, Dr Sidana explains that patients who have been treated with a BCMA-directed bispecific antibody may be treated with another bispecific antibody such as talquetamab, but data on the sequencing of different bispecific antibodies is limited. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Annual Congress in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
